Literature DB >> 29724657

Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy.

Christoph Wanner1, Dominique P Germain2, Max J Hilz3, Marco Spada4, Bruno Falissard5, Perry M Elliott6.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29724657     DOI： 10.1016/j.ymgme.2018.04.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN： 1096-7192            Impact factor:   4.797


× No keyword cloud information.
  2 in total

1.  Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly).

Authors:  Kolja Lau; Nurcan Üçeyler; Tereza Cairns; Lora Lorenz; Claudia Sommer; Magnus Schindehütte; Kerstin Amann; Christoph Wanner; Peter Nordbeck
Journal:  Mol Genet Genomic Med       Date:  2022-02-25       Impact factor: 2.473

2.  The Impact of Kidney Biopsy for Fabry Nephropathy Evaluation on Patients' Management and Long-Term Outcomes: Experience of a Single Center.

Authors:  Elena-Emanuela Rusu; Diana-Silvia Zilisteanu; Lucia-Mihaela Ciobotaru; Mihaela Gherghiceanu; Alexandru Procop; Ruxandra-Oana Jurcut; Adriana Octaviana Dulamea; Bogdan Marian Sorohan
Journal:  Biomedicines       Date:  2022-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.